Wednesday, June 10, 2026
🇺🇸 FDA

Drug profile · INN

adoptive

adoptive is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 5
News articles 0
Drug details — adoptive
Class
—
Route
—
Patents
20
Programs
5
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

adoptive is an FDA-listed pharmaceutical active ingredient.

Key facts

INN adoptive

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. adoptive immunotherapy Phase 3 · Chinese PLA General · Hepatocellular Carcinoma
  2. Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL) Phase 1 · United Therapeutics Europe · Urothelial Carcinoma
  3. CTM-N2D Phase 1 · CytoMed Therapeutics · Colorectal Cancer
  4. TIL in NSCLC Phase 1 · Disc Medicine · Respiratory tract diseases
  5. locally manufactured adoptive cellular therapy (ACT) product Phase 1 · Iovance Biotherapeutics · Malignant Pleural Effusion

Related patents

Browse patents

  1. US 12419870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12415843

    Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12397028

    Adoptive cellular therapy

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12295971

    Compositions and methods for enhancing adoptive T cell therapeutics

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12281329

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12121540

    CBL inhibitors and compositions for use in adoptive cell therapy

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12036256

    Adoptive cellular therapy

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12036241

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11932870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11925663

    Methods of managing tumor flare in adoptive immunotherapy

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11433131

    Adoptive cell therapy using spherical nucleic acids (SNAs)

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11413309

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11401506

    Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11318164

    Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy

    Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11096964

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9675633

    miRNA for treating cancer and for use with adoptive immunotherapies

    Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9512401

    B and T lymphocyte attenuator marker for use in adoptive T-cell therapy

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9074185

    Adoptive cell therapy with young T cells

    Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8541185

    Method of predicting responsiveness to autologous adoptive cell transfer therapy

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8383099

    Adoptive cell therapy with young T cells

    Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is adoptive?

adoptive is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.